within Pharmacolibrary.Drugs.ATC.C;

model C07AB14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.1066666666666667,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0.0003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Landiolol is an ultrashort-acting, highly selective beta-1 adrenergic receptor blocker. It is used mainly for rapid heart rate control in atrial fibrillation or atrial flutter, and for perioperative or ICU tachyarrhythmias. Landiolol is approved and in clinical use in countries such as Japan and several European nations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers receiving intravenous infusion.</p><h4>References</h4><ol><li><p>Krumpl, G, et al., &amp; Hodisch, J (2020). Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults. <i>BMC pharmacology &amp; toxicology</i> 21(1) 82–None. DOI:<a href=&quot;https://doi.org/10.1186/s40360-020-00462-x&quot;>10.1186/s40360-020-00462-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33239108/&quot;>https://pubmed.ncbi.nlm.nih.gov/33239108</a></p></li><li><p>Kunisawa, T, et al., &amp; Iwasaki, H (2015). Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients. <i>Journal of anesthesia</i> 29(2) 198–205. DOI:<a href=&quot;https://doi.org/10.1007/s00540-014-1908-5&quot;>10.1007/s00540-014-1908-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25186494/&quot;>https://pubmed.ncbi.nlm.nih.gov/25186494</a></p></li><li><p>Krumpl, G, et al., &amp; Husch, B (2018). Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites. <i>Journal of cardiovascular pharmacology</i> 71(3) 137–146. DOI:<a href=&quot;https://doi.org/10.1097/FJC.0000000000000554&quot;>10.1097/FJC.0000000000000554</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29112591/&quot;>https://pubmed.ncbi.nlm.nih.gov/29112591</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C07AB14;
